Jonny
@hsu_jonny
Co-Founder & CEO @blankbio_ | prev. @valence_ai @recursionpharma
🚀 Antiviral Challenge Results! 🚀 We're excited to announce the conclusion of the ASAP Discovery x OpenADMET Antiviral Challenge! A huge thank you to everyone who participated, collaborated, and shared learnings, helping us collectively advance open science. 🎯 Challenge…
Three weeks ago, we started building an AI game engine. But some models kept making things look... sloppy. So we turned finding the best one into a game. In three weeks, that game grew to 35K+ users across 135 countries. Introducing @designarena_ai, the fastest-growing…
It was really fun working on the app with the TxPert team at Valence! With the app, you can select a cell type, pick a perturbation, visualize a network of related genes, and select as many genes as you want to observe the transcriptional responses. Check it out 👇
1/ Introducing TxPert: a new model that predicts transcriptional responses across diverse biological contexts It’s designed to generalize across unseen single-gene perturbations, novel combinations of gene perturbations, and even new cell types 🧵
1/ At Valence Labs, @RecursionPharma's AI research engine, we’re focused on advancing drug discovery outcomes through cutting-edge computational methods Today, we're excited to share our vision for building virtual cells, guided by the predict-explain-discover framework 🧵
I'm excited to host @peter_skrinjar to chat about the dataset/benchmarking techniques used to identify some of the memorization issues with the latest models like AlphaFold3, Chai-1, Protenix, and more and why it wasn't easy to spot until now. We'll leave lots of time for Q&A!
We’re hosting @peter_skrinjar for a webinar to discuss his latest paper “Have protein co-folding methods moved beyond memorization?” 🚀 Peter will discuss the limitations of current co-folding models, the challenges of memorization in ligand pose prediction, and what is needed…
Today, we celebrate the Era of TechBio – ringing the @Nasdaq Opening Bell. The celebration comes on the heels of our business combination with Exscientia, and expanded partnerships and pipeline, including first-in-class and best-in-class programs across oncology and rare disease.…